Goldman Sachs Reaffirms Their Buy Rating on AstraZeneca (AZN)
Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca today and set a price target of £163.70.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
According to TipRanks, Sharma is a 3-star analyst with an average return of 4.4% and a 59.09% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Genmab.
In addition to Goldman Sachs, AstraZeneca also received a Buy from Bernstein’s Justin Smith in a report issued today. However, on June 30, Deutsche Bank maintained a Sell rating on AstraZeneca (LSE: AZN).
Based on AstraZeneca’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of p15.29 billion and a net profit of p3.08 billion. In comparison, last year the company earned a revenue of p13.96 billion and had a net profit of p3 billion
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AZN in relation to earlier this year.
Read More on GB:AZN:
Disclaimer & DisclosureReport an Issue
- AstraZeneca: Buy Rating Reaffirmed as Diversified Pipeline Offsets CARDIO-TTRansform Setback; 16,500 GBp Price Target Maintained
- Ionis, AstraZeneca report CARDIO-TTRansform trial misses primary endpoint
- AstraZeneca says CARDIO-TTRansform trial did not meet primary efficacy endpoint
- AstraZeneca’s Wainua misses primary goal in major ATTR-CM heart trial
- AstraZeneca autosomal dominant polycystic kidney disease drug gets orphan status
